RCEL Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.420

Open

4.380

VWAP

4.00

Vol

155.00K

Mkt Cap

136.00M

Low

4.210

Amount

673.00K

EV/EBITDA(TTM)

--

Total Shares

30.00M

EV

155.00M

EV/OCF(TTM)

--

P/S(TTM)

--

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

Show More

Events Timeline

(ET)

2026-01-21

10:10:00

Regencell Bioscience Shares Down 6.8% to $22.67

2026-01-20 (ET)

2026-01-20

12:10:00

Regencell Bioscience Shares Down 8.8% to $25.01

2026-01-20

10:10:00

Regencell Bioscience Shares Down 9.0% to $24.97

2026-01-16 (ET)

2026-01-16

10:10:00

Regencell Bioscience Shares Down 9.6% to $27.16

2026-01-15 (ET)

2026-01-15

12:10:00

Regencell Bioscience Shares Down 11.7% to $31.07

2026-01-15

10:10:00

Regencell Bioscience Shares Down 9.0% to $32.00

2026-01-13 (ET)

2026-01-13

12:10:00

Regencell Bioscience Shares Down 16.5% to $36.81

2026-01-13

10:10:00

Regencell Bioscience Shares Down 13.9% to $38.00

News

an image of Globenewswire

01-08Globenewswire

Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations

an image of Globenewswire

01-05Globenewswire

AVITA Medical Appoints Joe Woody as Board Director, Lou Panaccio Retires

an image of Globenewswire

2025-12-18Globenewswire

AVITA Medical CEO to Present at 44th Annual J.P. Morgan Healthcare Conference

an image of Globenewswire

2025-12-03Globenewswire

Agilon Health CEO Resignation Triggers 27% Stock Drop

an image of Benzinga

2025-11-20Benzinga

Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday

an image of Globenewswire

2025-11-18Globenewswire

Bragar Eagel & Squire, P.C. Urges Agilon, Soleno, Avita, and Coty Investors to Reach Out About Current Investigations

3 Analyst Rating

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

4.25

High

5.50

Current: 0.000

Low

3.00

Averages

4.25

High

5.50

Lake Street

Hold

maintain

$3

AI Analysis

2026-01-16

Reason

Lake Street

Price Target

$3

AI Analysis

2026-01-16

maintain

Hold

Reason

Lake Street raised the firm's price target on Avita Medical to $3.50 from $3 and keeps a Hold rating on the shares. Debt refinancing was "a necessary step to remove near-term liquidity concerns," says the analyst, who thinks full Q4 results and commentary around reimbursement trends could provide incremental confidence into the outlook, but stays at Hold as the firm waits to see business stabilization.

BTIG

Sell -> Neutral

upgrade

2025-11-20

Reason

BTIG

Price Target

2025-11-20

upgrade

Sell -> Neutral

Reason

BTIG upgraded Avita Medical to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company's "wounds are starting to heal or at least cannot get materially much worse," the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RCEL

Unlock Now

Valuation Metrics

The current forward P/E ratio for AVITA Medical Inc (RCEL.O) is -2.93, compared to its 5-year average forward P/E of -4.01. For a more detailed relative valuation and DCF analysis to assess AVITA Medical Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-4.01

Current PE

-2.93

Overvalued PE

10.40

Undervalued PE

-18.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

15.67

Current EV/EBITDA

-5.20

Overvalued EV/EBITDA

107.71

Undervalued EV/EBITDA

-76.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

6.08

Current PS

1.28

Overvalued PS

11.07

Undervalued PS

1.10

Financials

AI Analysis

Annual

Quarterly

Whales Holding RCEL

Trading Trends

People Also Watch

Frequently Asked Questions

What is AVITA Medical Inc (RCEL) stock price today?

The current price of RCEL is 4.36 USD — it has decreased -1.8 % in the last trading day.

What is AVITA Medical Inc (RCEL)'s business?

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

What is the price predicton of RCEL Stock?

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is4.25 USD with a low forecast of 3.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AVITA Medical Inc (RCEL)'s revenue for the last quarter?

AVITA Medical Inc revenue for the last quarter amounts to 18.00M USD, decreased -4.38 % YoY.

What is AVITA Medical Inc (RCEL)'s earnings per share (EPS) for the last quarter?

AVITA Medical Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

How many employees does AVITA Medical Inc (RCEL). have?

AVITA Medical Inc (RCEL) has 260 emplpoyees as of January 30 2026.

What is AVITA Medical Inc (RCEL) market cap?

Today RCEL has the market capitalization of 136.00M USD.